Biosimilars | Current Treatment | Nephrology | US/EU | 2016
The uptake of biosimilar erythropoiesis-stimulating agents (ESAs) varies from country to country, as well as by drug and manufacturer. European nephrologists have been able to prescribe ESAs to their chronic kidney disease (CKD) patients for a number of years, but no biosimilar ESAs are yet available to U.S. nephrologists. As new biosimilars near the market, including epoetin alpha biosimilars in the United States, it is important to understand how and why ESA biosimilar uptake is so varied. We surveyed French, German, and U.S. nephrologists about their familiarity with, use of, and attitude toward current biosimilars; the drivers and barriers to biosimilars’ uptake; and these physicians’ expectations for novel biosimilars.
Related Market Assessment Reports
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
